Nicotinamide for Skin Cancer Prevention: The ONTRAC Evidence

Nicotinamide (also called niacinamide) is the amide form of vitamin B3 that does not cause flushing. In 2015, it became the first oral supplement proven in a large randomized controlled trial to reduce skin cancer incidence — the Australian ONTRAC trial published in the New England Journal of Medicine. This result was not marginal — it represented a 23% reduction in new non-melanoma skin cancers (NMSC) and a 20% reduction in new actinic keratoses (precancers), using an inexpensive, well-tolerated vitamin at 500 mg twice daily.

Quick Answer

Nicotinamide at 500 mg twice daily (1000 mg total) reduces new non-melanoma skin cancers by 23% in high-risk individuals by enhancing NAD+-dependent DNA repair following UV damage. It also reduces actinic keratoses by 20% and prevents UV-induced immunosuppression. Benefits require continuous use — they disappear within 6 months of stopping.

The ONTRAC Trial

The phase 3, double-blind, placebo-controlled ONTRAC trial enrolled 386 high-risk Australians (each with at least 2 NMSCs in the previous 5 years). Participants received either nicotinamide 500 mg twice daily or placebo for 12 months.

Key results:

• 23% reduction in new NMSC (both basal cell carcinoma and squamous cell carcinoma)
• 20% reduction in new actinic keratoses at 12 months
• 30% reduction in new NMSCs at 6 months (effects were rapid)
• No significant adverse effects compared to placebo
• Effects were lost within 6 months of stopping — confirming the mechanism is enhanced repair, not permanent cancer prevention

This trial established nicotinamide as the first evidence-based oral chemoprevention for skin cancer.

How Nicotinamide Protects Against Skin Cancer

UV radiation depletes NAD+ (nicotinamide adenine dinucleotide) in skin cells. NAD+ is the essential coenzyme for:

• PARP enzymes — detect and repair UV-induced DNA damage (cyclobutane pyrimidine dimers, 6-4 photoproducts). Without adequate NAD+, PARPs cannot function, and DNA damage accumulates toward mutagenesis
• SIRT enzymes — regulate cellular stress responses and apoptosis of damaged cells
• Cellular energy — ATP production in mitochondria for the energy-intensive process of DNA repair
• Immune surveillance — UV depletes NAD+ in Langerhans cells, causing immunosuppression that allows damaged cells to escape immune detection

Nicotinamide replenishes NAD+ pools, restoring all four protective mechanisms simultaneously. This is not an antioxidant effect — it is a metabolic rescue of the cell's repair machinery.

Who Should Take Nicotinamide

Strong indication (highest benefit):

• History of 2+ non-melanoma skin cancers
• Extensive actinic keratoses
• Organ transplant recipients (40-100x NMSC risk)
• Heavy lifetime UV exposure history

Reasonable indication:

• History of 1 NMSC
• Fair skin with significant sun exposure
• Photosensitizing medication use
• Immunosuppressed individuals

Unclear benefit:

• No personal history of skin cancer and low UV exposure
• Melanoma prevention (ONTRAC focused on NMSC; melanoma data is preliminary)

Dosing

• Established dose: 500 mg twice daily (as used in ONTRAC)
• Form: Nicotinamide (niacinamide), NOT nicotinic acid (which causes flushing)
• Timing: Morning and evening, with or without food
• Duration: Continuous — benefits require ongoing supplementation
• Cost: Approximately $5-15/month, making it one of the most cost-effective cancer prevention interventions available

Important Distinctions

Nicotinamide vs Niacin: Nicotinamide (niacinamide) does NOT cause flushing, does NOT affect cholesterol, and is the form used in the ONTRAC trial. Niacin (nicotinic acid) causes flushing and has different metabolic effects.

Nicotinamide vs Nicotinamide Riboside (NR): NR is a more expensive NAD+ precursor. No skin cancer prevention trials have been conducted with NR. Until such data exists, standard nicotinamide remains the evidence-based choice.

Not a sunscreen replacement: Nicotinamide enhances DNA repair but does not block UV radiation. It works best as a layer within a comprehensive sun protection strategy including topical SPF.

Safety

Nicotinamide has an excellent safety profile at 1000 mg daily. The ONTRAC trial showed no significant difference in adverse events between treatment and placebo groups. At very high doses (>3g daily), rare hepatotoxicity has been reported, but this is well above the recommended dose. There are no significant drug interactions. It is safe with immunosuppressive medications.

FAQ

Does nicotinamide prevent melanoma? The ONTRAC trial was not powered to detect melanoma reduction. Preliminary data from the same trial showed a non-significant trend toward fewer melanomas. A dedicated melanoma prevention trial is needed. Currently, nicotinamide is recommended specifically for NMSC prevention.

Can I take nicotinamide if I have no skin cancer history? Yes, it is safe and inexpensive. However, the strongest evidence supports use in high-risk individuals. For the general population, sunscreen adherence provides greater absolute risk reduction.

Is topical niacinamide enough, or do I need oral? The ONTRAC evidence is specifically for oral nicotinamide. Topical niacinamide (typically 4-5% in skincare) provides local benefits for barrier function and pigmentation but has not been studied for skin cancer prevention at the same rigor as oral dosing.

Related Articles

• Nicotinamide Riboside Skin Guide
• Supplements for Skin Cancer Prevention
• Internal Sunscreen Supplements
• Polypodium Leucotomos Sun Protection
• Niacinamide Supplement for Skin

Track your supplements in Optimize.